Skip to main content
Clinical Trials/NCT02831803
NCT02831803
Completed
Not Applicable

A Pilot Study to Evaluate the Feasibility of Walnut and Extra Virgin Olive Oil Supplementation in Older Adults Being Treated for Hypertension

Wake Forest University Health Sciences0 sites27 target enrollmentOctober 2014
ConditionsHypertension

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypertension
Sponsor
Wake Forest University Health Sciences
Enrollment
27
Primary Endpoint
Retention of study participants
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study is designed to test the feasibility of asking older adults with high blood pressure to supplement their daily diets with walnuts and extra-virgin olive oil.

Detailed Description

Even though cardiovascular disease (CVD) continues to be the leading cause of death in the United States, Americans have yet to widely adopt evidence-based dietary modifications necessary to reduce CVD risk factors. Encouraging evidence from the Prevención con Dieta Mediterránea (PREDIMED) trial indicates that adding olive oil and nuts to the diets of older adults in Spain substantially impacted CVD risk factors and events. A large trial testing EVOO and nuts in a U.S. population is needed to determine if supplementing with EVOO and nuts can reduce risk of cardiovascular events and mortality in adults living in the U.S. Prior to launching a large trial, it is important to assess whether adults 55 and older would be interested in participating in a supplementation trial such as PREDIMED. Additionally, it is important to assess if they are willing to consume the nuts and EVOO and attend study related-data collection visits.

Registry
clinicaltrials.gov
Start Date
October 2014
End Date
January 2016
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Being treated for hypertension-defined by being prescribed at least one hypertension medication; willing to comply with study visits, as outlined in the protocol; able to read and speak English; no allergies or hypersensitivities to olive oil or nuts; ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Plans to move from the study area in the next 8 weeks; dementia that is medically documented or suspected; homebound for medical reasons; cancer diagnosis and/or treatment in the last 3 years.

Outcomes

Primary Outcomes

Retention of study participants

Time Frame: 8 weeks

To estimate retention (measured by number attending the 8 week closeout visit) of men and women being treated for hypertension in the 8 week study.

Adherence to consuming walnuts and EVOO

Time Frame: 8 weeks

To assess adherence to consuming the nut and oil supplements (measured by daily diary of supplement intake) over the course of the study.

Secondary Outcomes

  • HDL cholesterol(8 weeks)
  • Blood pressure(8 weeks)
  • Weight(8 weeks)
  • Adverse events(8 weeks)

Similar Trials